Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma.

Lung metastases in adenoid cystic carcinoma (ACC) usually have indolent growth and the optimal timing to start systemic therapy is not established. We assessed ACC lung metastasis tumor growth dynamics and compared the prognostic value of time to progression (TTP) and tumor volume doubling time (TVDT). The study included ACC patients with ≥1 pulmonary metastasis (≥5 mm) and at least 2 chest computed tomography scans. Radiology assessment was performed from the first scan showing metastasis until treatment initiation or death. Up to 5 lung nodules per patient were segmented for TVDT calculation. To assess tumor growth rate (TGR), the correlation coefficient (r) and coefficient of determination (R The study included 75 patients. Sixty-seven patients (89%) had lung-only metastasis on first CT scan. The TGR was overall constant (median R Most ACC lung metastases have a constant TGR. TVDT may be a better prognostic indicator than TTP in lung-metastatic ACC. TVDT can be estimated by single longitudinal measurement in clinical practice.

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: EADL, LGS, ZY, FB, COH, MS, KAW, WL, EYH, AEN, CDF, SK, MG have no conflict of interest. RF reports the following: Paid consultant/advisory board member: Elevar Therapeutics, Prelude Therapeutics, Regeneron, Sanofi, Eisai, and Remix. Royalties: UpToDate. Recipient of funds given to MD Anderson Cancer Center Ayala, Merck, Genentech, Pfizer, Nanobiotix, EMD Serono, Viracta, Seagen, and ISA Therapeutics. KW reports consulting fees from BluPrint Oncology.